• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Medical Journal of Shree Birendra Hospital >Evaluation of Visual Function Test of Central Serous Chorioretinopathy After Intravitreal Bevacizumab
【24h】

Evaluation of Visual Function Test of Central Serous Chorioretinopathy After Intravitreal Bevacizumab

机译：玻璃体内贝伐单抗治疗后中央性浆液性脉络膜视网膜病变的视觉功能评估

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Central Serous Chorioretinopathy (CSCR) is a condition of unknown origin characterised by a serous detachment of the macula, affecting young healthy adults mostly men between the age of 20- 50 years. It is postulated to occur secondary to a leak from the choriocapillaries through the Retinal Pigment Epithelium (RPE). This study was carried out to evaluate the visual function test of CSCR after intravitreal Bevacizumab. Methods: This is a hospital based, prospective, interventional, non-comparative study conducted in a tertiary level eye hospital in Nepal from 2016 January to 2017 January. The study included 15 eyes of 15 patients with chronic CSCR, All patients were injected with intravitreal Avastin (IVA) 1.25 mg (0.05 mL). At baseline and follow up visits, patients had contrast sensitivity, stereopsis, colour vision, BCVA, IOP assessment, FFA, dilated fundus examination, and OCT imaging was used for measurement of central macular thickness. Results: The mean age of patients was 35 years (26–47 years), 12 (80%) patients were males and three (20%) were females. 13 out of 15 subjects received one injection while the remaining two cases had two injections. All eyes had gained two or more lines improvement in BCVA at the end of follow up. The mean baseline CRT for all patients was 533 ±79.5 lm (range, 412–677), decreased to 253± 39.2 lm (range, 192–343) after three months with statistically significant (p ;0.001 Wilcoxon sign rank test). Contrast sensitivity by Wilcoxon sign rank test was statistically significant with p value 0.003. Conclusions: Bevacizumab was associated with visual function improvement and reduced neurosensory detachment without adverse events in patients with CSCR.
机译：简介：中枢性浆液性脉络膜视网膜病变（CSCR）是一种来源不明的疾病，其特征是黄斑浆液性脱离，影响年轻健康的成年人，大多数是20至50岁的男性。假定它是继发于脉络膜毛细血管通过视网膜色素上皮（RPE）渗漏后发生的。进行这项研究以评估玻璃体内贝伐单抗治疗后CSCR的视觉功能测试。方法：这是一项基于医院的前瞻性，干预性，非对照研究，于2016年1月至2017年1月在尼泊尔的一家三级眼科医院进行。该研究包括15例慢性CSCR患者的15眼，所有患者均注射1.25 mg（0.05 mL）玻璃体内阿瓦斯汀（IVA）。在基线和随访期间，患者进行了对比敏感性，立体视，色觉，BCVA，IOP评估，FFA，眼底扩张检查，OCT成像用于测量中央黄斑厚度。结果：患者的平均年龄为35岁（26-47岁），男性为12位（80％），女性为3位（20％）。 15名受试者中有13名接受了一次注射，其余2例进行了两次注射。随访结束时，所有眼睛的BCVA均获得了两行或更多行改善。所有患者的平均基线CRT为533±79.5 lm（范围412-677），三个月后降至253±39.2 lm（范围192-343），具有统计学意义（p <0.001 Wilcoxon符号秩检验）。 。 Wilcoxon符号等级检验的对比敏感性具有统计学意义，p值为0.003。结论：贝伐单抗与CSCR患者的视觉功能改善和神经感觉脱离减少无不良事件相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号